PMV Pharmaceuticals, Inc. (PMVP)

5.42 -0.07 (-1.28%) At close: 04:00PM EDT

PMV Pharmaceuticals, Inc.

8 Clarke Drive
Suite 3
Cranbury, NJ 08512
United States
609 642 6670
https://www.pmvpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 54

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David H. Mack Ph.D.	Co-Founder, CEO, Pres & Director	889.2k	2.17M	1962
Dr. Arnold J. Levine Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	140k	N/A	1940
Mr. Winston Kung M.B.A.	COO & CFO	673.12k	676.34k	1976
Dr. Deepika Jalota Pharm.D.	Chief Regulatory & Quality Assurance Officer	579.96k	87.59k	1977
Dr. Leila Alland M.D.	Chief Medical Officer	685.23k	708.15k	1962
Dr. Thomas E. Shenk Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1947
Mr. Robert Ticktin	Gen. Counsel & Company Sec.	N/A	N/A	1962
Mr. Tim Smith	Sr. VP & Head of Corp. Devel.	N/A	N/A	N/A
Dr. Binh Vu Ph.D.	Sr. VP of Drug Discovery & CMC	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Corporate governance

PMV Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 February 2023 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.